Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology firm focusing on tumor-selective immuno-oncology therapies, announced that CEO René Russo will participate in the "Novel IO Panel" at the Cowen 42nd Annual Healthcare Conference on March 7, 2022, at 10:30 a.m. ET. The event will be available via live webcast on the company’s website, with a replay accessible for 30 days post-presentation. Xilio aims to enhance cancer treatment using its proprietary GPS platform to create targeted biologics, including several promising therapeutic candidates.
- None.
- None.
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a virtual panel titled, “Novel IO Panel,” during the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022, at 10:30 a.m. ET.
A live webcast will be available in the Investors and Media section of the Xilio Therapeutics’ website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics’ website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX202, a tumor-selective IL-2; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15. For more information, please visit www.xiliotx.com.
For Investor Inquiries:
Chelcie Lister, THRUST Strategic Communications
chelcie@thrustsc.com
For Media Inquiries:
Dan Budwick
dan@1abmedia.com
FAQ
What is Xilio Therapeutics participating in on March 7, 2022?
Who is the CEO of Xilio Therapeutics?
Where can I watch the Xilio Therapeutics conference presentation?
What are some product candidates in Xilio Therapeutics' pipeline?
What time is the Cowen Healthcare Conference event featuring Xilio Therapeutics?
